Protocol Ledger

NCT05269173 · Phase II · COMPLETED

Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease

Interventional Phase II clinical trial protocol NCT05269173 sponsored by Capital Medical University in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-29 Enrollment: 240 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05269173
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05269173
Protocol FieldVerified Registry Value
NCT IdentifierNCT05269173
Consolidated Lead SponsorCapital Medical University
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment240 participants (ACTUAL)
Registered Start Date2020-10-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05269173
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI